Azathioprine

Monopgraph
Therapeutic action
Azathioprine is an imidazole derivative of 6-mercaptopurine (6-MP) with immunosuppressive properties. It’s most commonly applied at:
- Organ transplants: kidney, heart and liver.
- From moderate to severe inflammatory bowel disease.
- Multiple sclerosis clinically definite relapsing-remitting.
- Oncohematologic disease.
- Severe forms of: rheumatoid arthritis, systemic lupus erythematosus, dermatomyositis, polymyositis, autoimmune chronic active hepatitis, pemphigus vulgaris, polyarteritis nodosa, autoimmune hemolytic anemia, idiopathic thrombocytopenic purpura, and pyoderma gangrenosum.
Additional information
Thiopurine methyltransferase (TPMT) catalyses the S-methylation of thiopurines, including azathioprine, 6-mercaptopurine (6-MP) and thioguanine. Polymorphisms in the TPMT gene give rise to different alleles that make the protein more susceptible to degradation, thereby reducing its activity. This leads to the intracellular accumulation of high concentrations of thioguanine nucleotides, which are highly toxic (Coulthard et al., 2005).
Approximately 20 alleles have currently been described. The wild-type *1 allele and the *2, *3A, *3B and *3C alleles are the most common.
In White populations, approximately 10% of patients are heterozygous and have intermediate enzymatic activity, requiring a dose reduction of 35–50%. Approximately 1 in 300 patients is TPMT deficient and may tolerate only 10% of the standard dose (Evans et al., 1991; Relling et al., 1999).
When the azathioprine dose is appropriately adjusted in these patients, they generally tolerate full doses of other therapeutic agents, resulting in improved treatment efficacy.
Metabolism
Azathioprine is a prodrug that is converted in vivo into 6-MP, a purine analogue, and partly into methylnitroimidazole.
Through a series of intracellular enzymatic reactions involving hypoxanthine phosphoribosyltransferase (HPRT), 6-MP is converted into thioguanine nucleotides. These nucleotides are incorporated into DNA and RNA, causing cytotoxicity.
In addition, one of its metabolites, S-methylthioinosine monophosphate, inhibits de novo purine synthesis.
The main mechanism of intracellular inactivation of thioguanine nucleotides is S-methylation catalysed by thiopurine methyltransferase (TPMT).
These compounds are also eliminated through oxidation catalysed by xanthine oxidase (XO). Both pathways reduce the concentration of active thioguanine nucleotides.
Conclusions
Testing for TPMT polymorphisms before administering azathioprine or other thiopurines is useful for preventing drug-associated myelotoxicity.
Dose adjustment in patients with reduced enzymatic activity who carry the *2, *3A or *3C alleles consists of:
i) a dose reduction of 35–50% in heterozygous patients; and
ii) administration of approximately 10% of the standard dose in patients who are homozygous for reduced-function alleles.
Bibliography
- Coulthard S, et al. The thiopurines: an update. Invest New Drugs. 2005 Dec;23(6):523-32.
- Evans WE, et al. Altered mercaptopurine metabolism, toxic effects, and dosage requirement in a thiopurine methyltransferase-deficient child with acute lymphocytic leukemia. J Pediatr. 1991 Dec;119(6):985-9.
- Relling MV, et al. Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. J Natl Cancer Inst. 1999 Dec 1;91 (23):2001-8
Additional information
David Páez López-Bravo Licenciado en Medicina Especialidad en Oncología Médica